Metabolic syndrome, anxiety, depression and suicidal tendencies in post-traumatic stress disorder and schizophrenic patients [Metabolički sindrom, anksioznost, depresija i suicidalnost kod oboljelih posttraumatskog stresnog poremećaja i shizofrenije] by Maslov, Boris et al.
Coll. Antropol. 33 (2009) Suppl. 2: 7–10
Original scientific paper
Metabolic Syndrome, Anxiety, Depression and
Suicidal Tendencies in Post-Traumatic Stress
Disorder and Schizophrenic Patients
Boris Maslov1, Darko Mar~inko2, Ru`a Mili~evi}1, Dragan Babi}1, Veljko \or|evi}2
and Miro Jakovljevi}1,2
1 School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina
2 Department of Psychiatry, University Hospital Centre Zagreb, Zagreb, Croatia
A B S T R A C T
Persons with schizophrenia and post-traumatic stress disorder (PTSD) tend to have higher psychiatric and somatic
morbidity. They typically have higher rates of substances abuse (including smoking), more prevalent obesity, diabetes
mellitus, and cardiovascular disease (CVD). This is especially well seen in case of the metabolic syndrome, with a num-
ber of published studies on psychiatric patients in the last few years. This study investigated the associations between
metabolic syndrome, anxiety, depression and suicidal tendency in schizophrenic and combat-related PTSD patients con-
trolled by healthy controls. Higher rates of anxiety, depression and recent life changes scores in participants with meta-
bolic syndrome were recorded compared to those without metabolic syndrome. Suicidal tendencies were equally present
in both groups.
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Introduction
Persons with schizophrenia and PTSD tend to have
higher morbidity. They typically have high rates sub-
stance abuse (including smoking), obesity, diabetes me-
llitus, and cardiovascular disease (CVD)1. Studies have
shown that schizophrenic patients have a 50% to 300%
increased risk of death due to medical causes2,3. There
are only few reports about metabolic syndrome in PTSD
patients. In our earlier study4 we have found that meta-
bolic syndrome (MetSy) was significantly higher in schi-
zophrenic patients compared to healthy controls and
there were no differences between schizophrenic and
PTSD patients. We have also investigated metabolic syn-
drome and depression in war veterans with post-trau-
matic stress disorder5. Suicidal attempts and suicide are
complications in some schizophrenic and PTSD patients.
Earlier papers of our team pointed out the role of lower
cholesterol in the context of suicidal tendency for pa-
tients of different diagnostic groups of psychotic pa-
tients6–10 and some parameters of suicidal behavior in
combat related PTSD patients11. This study investigated
association between metabolic syndrome, anxiety, depres-
sion and suicidal tendency in schizophrenic and com-
bat-related PTSD patients controlled by healthy controls.
Materials and Methods
Subjects
Our investigation included 450 participants. The
group of schizophrenic patients (n=205) comprised of
108 patients treated at the Department of Psychiatry,
Clinical Hospital Mostar and 97 patients treated in am-
bulatory setting. The control group included PTSD pa-
tients (n=140) and healthy controls (n=140). The con-
trols were matched for age and gender.
Clinical evaluations
The diagnosis of schizophrenia and PTSD was made
according to diagnostic criteria of the International Sta-
tistical Classification of Diseases and Related Health
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Problems12. The diagnosis of the metabolic syndrome
was made according to ATP-III criteria. Clinical evalua-
tion was performed by the trained psychiatrists. Anxiety
was assessed by Hamilton anxiety scale and depression
was assessed by Hamilton depression scale.
Ethics
All subjects gave written informed consent to partici-
pate in the study. This study was approved by the Medi-
cal Ethics Committee. The exclusion criteria were diag-
nosis of substance abuse and alcoholism.
Biochemical measurements
Blood samples were collected from all subjects at 8.30
a.m. after an overnight fasting, and serum concentration
of lipids was determined by enzyme analysis, immedi-
ately after the blood collection. The assays were done us-
ing commercial kits (Olympus Diagnostic GmbH, Ham-
burg, Germany) on Olympus AU 600 automatic analyzer.
Statistical analysis
The results were expressed as mean values and stan-
dard deviations. Student t-test was used to compare two
groups after normal data distribution in some variables
had been demonstrated by Kolmogorov-Smirnov test.
The differences in the non-parametric variables between
groups were assessed using c2-test. In all tests, the crite-
rion of significance was p<0.05. Statistical analysis of re-
sults was done by SPSS 11 (SPSS for Windows 11.0,
SPSS, Chicago, IL, USA).
Results
The results have been shown in the form of the few
tables. The scores on Ham-D, Ham-A and RLCQ were
significantly higher in participants with metabolic syn-
drome compared to those without metabolic syndrome
(t-test; p<0,001; Table 1). RLCQ score was significantly
higher in schizophrenic patients with metabolic syn-
drome (646.74±238.76) compared to schizophrenic pa-
tients without metabolic syndrome (494.52±165.86)
(t-test; p<0.001). In the group of healthy controls, the
scores on Ham-D, Ham-A and RLCQ were significantly
higher in participants with metabolic syndrome com-
pared to those without metabolic syndrome (t-test; p<
0.001). RLCQ score was significantly higher in PTSD pa-
tients with metabolic syndrome (526.85±144.48), com-
pared to PTSD patients without metabolic syndrome
(439.43±104.91) (p<0.001). There was no significant dif-
ference in history of suicide attempt between schizo-
phrenic patients with metabolic syndrome compared to
those without (c2=0.019; p=0.890). Metabolic syndrome
was significantly more presented in PTSD patients with
suicide attempt (20.0%), compared to PTSD patients
without suicide attempt (7.7%), (p<0.01). There were no
significant differences in suicide attempts and frequency
of some components of metabolic syndrome in schizo-
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TABLE 1
DIFFERENCES IN HAM D, HAM A AND RLCQ TEST BETWEEN PARTICIPANTS WITH AND WITHOUT METABOLIC SYNDROME
Scale
X±SD
T p*
Without MetSy With MetSy
Ham-D 7.44±6.24 10.44±7.27 4.56 <0.001
Ham-A 5.49±3.93 6.94±4.05 3.78 <0.001
RLCQ 451.20±143.93 583.30±208.31 7.47 <0.001
TABLE 2
INFLUENCE OF DEPRESSION, ANXIETY AND STRESS ON INCIDENCE OF METABOLIC SYNDROME IN SCHIZOPHRENIC,
PTSD PATIENTS AND HEALTHY CONTROLS
Group Scale
X±SD
t P
Without MetSy With MetSy
Schizophrenia Ham D 11.36±6.86 13.18±7.91 1.76 0.080
Ham A 8.00±4.32 8.55±4.42 0.89 0.372
RLCQ 494.52±165.86 646.74±238.76 5.25 <0.001
Healthy controls Ham D 3.04±1.92 5.65±2.18 6.97 <0.001
Ham A 2.66±1.61 4.10±1.23 5.09 <0.001
RLCQ 411.13±124.61 497.20±133.07 3.62 <0.001
PTSD Ham D 7.72±4.77 8.90±6.15 1.10 0.273
Ham A 5.72±2.45 6.04±3.17 0.59 0.559
RLCQ 439.43±104.91 526.85±144.48 3.49 <0.001
phrenic and PTSD patients. Schizophrenic and PTSD
patients with hypertriglyceridaemia and low HDL made
frequently suicide attempts.
Discussion
The results of this study show that participants with
metabolic syndrome have significantly higher anxiety,
depression and recent life changes than those without
metabolic syndrome. After divided participants in the
three groups (schizophrenic patients, PTSD patients and
healthy controls) we have found that recent life changes
score was significantly higher in all of groups with meta-
bolic syndrome but anxiety and depression scores were
significantly higher only in healthy controls with meta-
bolic syndrome (comparing to those without metabolic
syndrome) but no in the groups of schizophrenic and
PTSD patients. Although, schizophrenic and PTSD pa-
tients with metabolic syndrome have non-significantly
higher scores of anxiety and depression compared to
same groups without metabolic syndrome. It could
means that anxiety and depression may be a risk factor
for some unhealthy habits that lead to development of
metabolic syndrome. It is hypothesized that a predisposi-
tion towards abdominal obesity places schizophrenia pa-
tients at risk for development of both type II DM and the
metabolic syndrome13. There were no differences in sui-
cidal attempts between schizophrenic patients with and
without metabolic syndrome but there was a difference
in PTSD patients. PTSD is multisystemic mental disor-
der with numerous psychiatric and somatic comorbidi-
ties14–16. PTSD patients with metabolic syndrome have
significantly higher number of suicidal attempts than
PTSD patients without metabolic syndrome. Possible ex-
planation could be that metabolic syndrome can increa-
ses the level of severity disease in PTSD and suicidal be-
havior is one of tragic complications in this group of
patients.
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TABLE 3
FREQUENCY OF METABOLIC SYNDROME COMPARED TO SUICIDAL ATTEMPT IN SCHIZOPHRENIC AND PTSD PATIENTS
Group
Suicide
attempt
Diagnosis of MetSy
Total N (%)No Yes
N (%) N (%)
Schizophrenia Total 111 (100.0) 94 (100.0) 205 (100.0)
Yes 40 (36.0) 33 (35.1) 73 (100.0)
No 71 (64.0) 61 (64.9) 132 (100.0)
PTSD Total 65 (100.0) 40 (100.0) 105 (100.0)
Yes 5 (7.7) 8 (20.0) 13 (100.0)
No 60 (92.3) 32 (80.0) 92 (100.0)
TABLE 4
SUICIDAL ATTEMPTS IN SCHIZOPHRENIC AND PTSD PATIENTS COMPARED TO FREQUENCY OF
METABOLIC SYNDROME COMPONENTS
Group Components of MetSy
Suicide attempt
c2 pNo Yes
N (%) N (%)
Schizophrenia Abdominal obesity 72 (80.0) 20 (17.4) 0.23 0.633
Hypertension 96 (83.5) 19 (16.5) 0.70 0.401
Hyperglycaemia 57 (85.1) 10 (14.9) 0.86 0.354
Hypertriglyceridaemia 94 (81.7) 21 (18.3) 0.01 0.909
Low HDL 44 (75.9) 14 (24.1) 1.68 0.195
PTSD Abdominal obesity 57 (90.5) 6 (9.5) 0.19 0.665
Hypertension 56 (93.3) 4 (6.7) 2.29 0.130
Hyperglycaemia 31 (88.6) 4 (11.4) 0.04 0.841
Hypertriglyceridaemia 46 (90.2) 5 (9.8) 0.06 0.801
Low HDL 23 (88.5) 3 (11.5) 0.03 0.854
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METABOLI^KI SINDROM, ANKSIOZNOST, DEPRESIJA I SUICIDALNOST KOD OBOLJELIH OD
POSTTRAUMATSKOG STRESNOG POREME]AJA I SHIZOFRENIJE
S A @ E T A K
Oboljeli od shizofrenije i post-traumatskog stresnog poreme}aja (PTSP) imaju zna~ajan psihijatrijski i somatski
komorbiditet. Obi~no imaju visoku u~estalost ovisnosti (osobito pu{enja), debljine, {e}erne bolesti i kardiovaskularnih
bolesti. Vi{e je objavljenih radova zadnjih godina koji opisuju metaboli~ki sindrom u psihijatrijskih bolesnika. Ovo istra-
`ivanje povezuje parametre metaboli~kog sindroma, anksioznost, depresiju i suicidalnost, kod oboljelih od shizofrenije i
PTSP-a, u usporedbi sa zdravim ispitanicima. Na ukupnom promatranom uzorku, prona|ena je vi{a izra`enost anksi-
oznosti, depresije i nedavnih `ivotnih promjena, kod ispitanika s metaboli~kim sindromom u usporedbi s onima koji
nemaju metaboli~ki sindrom. Suicidalnost nije bila zna~ajno razli~ita izme|u bolesnika s metaboli~kim sindromom u
usporedbi s onima koji nemaju metaboli~ki sindrom.
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